← Human Trials & Peer-Reviewed Studies
Recombinant growth hormone therapy for X-linked hypophosphatemia in children.
Plain-language guide to PMID 34618915 (2021): systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 34618915
- Journal
- The Cochrane database of systematic reviews
- Year
- 2021
- Study type
- Systematic Review
- Authors
- Smith S et al. (2 authors)
- DOI
- 10.1002/14651858.CD004447.pub3
What This Paper Covers, in Plain Language
What It Covers
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a systematic review.
GRADE criteria were used to assess the certainty of the evidence for each outcome.
Why It Was Studied
This is an updated version of a previously published review.
Two authors independently assessed studies for risk of bias and extracted data from eligible studies.
Who the Included Studies Covered
PubMed indexes the participants as children.
Date of the most recent search: 12 January 2021 SELECTION CRITERIA: All randomized controlled studies or quasi-randomized controlled studies comparing growth hormone (alone or combined with conventional treatment) with either placebo or conventional treatment alone in children with X-linked hypophosphatemia.
How the Review Was Done
The researchers searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
In addition, the researchers searched the Cochrane Central Register of Controlled Trials, Ovid MEDLINE and the reference lists of identified trials and other reviews.
The researchers also undertook some additional handsearching of relevant journals and conference proceedings.
What Was Measured
Two authors independently assessed studies for risk of bias and extracted data from eligible studies.
The subject headings attached to it are Body Height, Familial Hypophosphatemic Rickets, Growth Hormone and Human Growth Hormone.
What This Means in Plain Language
This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (The Cochrane database of systematic reviews), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.